Definition
Multicentric Castleman disease is a systemic disorder of lymph nodes characterized by inflammatory symptoms including fever, night sweats, cachexia, malaise, and lymphadenopathy together with laboratory abnormalities including anemia and hypoalbuminemia. Together these symptoms may be life threatening. The diagnosis is based on specific pathological findings in affected lymph nodes. In individuals infected with HIV, multicentric Castleman disease is almost exclusively caused by infection with a cancer-causing herpesvirus, Kaposi sarcoma-associated herpesvirus (KSHV, also known as human herpesvirus 8). This may be considered a separate entity from the non-KSHV-related or idiopathic form of multicentric Castleman disease and from unicentric forms of Castleman disease. While these disorders have pathological and clinical similarities, the KSHV-related form is distinguished by its pathological characteristics and unique viral etiology.
Introduction
One of the earliest signs of...
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
References
Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood. 2001;97(8):2526.
Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, et al. Brief communication: Rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147(12):836–9.
Casper C, Nichols WG, Huang M-L, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood. 2004;103(5):1632–4.
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266(5192):1865–9.
Gérard L, Michot JM, Burcheri S, Fieschi C, Longuet P, Delcey V, et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood. 2012;119(10):2228–33.
Gopal S, Wood WA, Lee SJ, Shea TC, Naresh KN, Kazembe PN, et al. Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Blood. 2012;119(22):5078–87.
Oksenhendler E, Duarte M, Soulier J, Cacoub P, Welker Y, Cadranel J, et al. Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10(1):61.
Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, Agbalika F. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000;96(6):2069.
Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol. 2012;3:73.
Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol. 2009;20(4):775–9.
Soulier J, Grollet L, Oksenhendler E, Cacoub P, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86(4):1276–80.
Uldrick TS, Wang V, O’Mahony D, Aleman K, Wyvill KM, Marshall V, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without multicentric Castleman disease. Clin Infect Dis. 2010;51(3):350–8.
Uldrick TS, Polizzotto MN, Aleman K, O’Mahony D, Wyvill KM, Wang V, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117(26):6977–86.
Waterston A, Bower M. Fifty years of multicentric Castleman’s disease. Acta Oncol. 2004;43(8):698–704.
Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood. 1989;74(4):1360–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Note
This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute.
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this entry
Cite this entry
Polizzotto, M.N., Uldrick, T.S., Yarchoan, R. (2013). Multicentric Castleman Disease. In: Hope, T., Stevenson, M., Richman, D. (eds) Encyclopedia of AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9610-6_6-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9610-6_6-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-9610-6
eBook Packages: Springer Reference MedicineReference Module Medicine